Navigation Links
Hard To Treat Diseases (HTDS) Slavica BioChem Update on Research Activities
Date:4/22/2009

BELGRADE, April 22 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) www.htdsmedical.com - HTDS chief scientist Dr. Sanja Pekovic provided updates from a recent medical convention held in Antwerpen; Joint Meeting 2009 Anatomische Gesellschaft - Nederlandse Anatomen Vereniging, Antwerpen, 27-30 March 2009.

Dr. Pekovic reported on the results of recent positive testing being conducted related to the CNS disorder multiple sclerosis and in suppression of reactive astrogliosis after brain injury. This led to a number of preliminary talks for future collaboration with other scientists working in the field. A more detailed review of the research results will be posted separately on the Pink Sheets as a supplementary filing shortly. Notably, this work was supported by the European Cooperation in the Field of Scientific and Technical Research (COST) organization.

Dr. Pekovic also reported the scientific team has started some in vitro studies of purine nucleoside analogues (ribavirin, tiazofurin, the drugs we are investigating) effects on microglial cell culture (there is no current data in the literature about their effect on microglia) in collaboration with professor Thomas Herdegen from Kiel University, Germany, who is also a member of COST as a representative of Germany. Over the last 3 months in the lab, our technicians have learned how to establish microglial cell culture, a valuable next step in the continued research.

HTDS will be providing additional funding to further this work, at the IBISS INSTITUT ZA BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC for Project 143005 headed by professor Mirjana Stojiljkovic.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New treatment shows promise against recurrent gynecologic cancers
2. Leading Critical Care Doctor Shifts From Treatment to Empowerment by Helping Americans Create Optimal Health in Their Lives
3. First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure
4. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
5. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
6. Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
7. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
8. For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
9. Targeted Treatments Show Mettle Against Advanced Cancers
10. North Carolina Give Kids A Smile! Project Treats Close to 20,000 Children
11. Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology: